Research progress of conversion therapy in pancreatic cancer
10.3781/j.issn.1000-7431.2023.2306-0318
- VernacularTitle:胰腺癌转化治疗的研究进展
- Author:
Yuxin WANG
1
;
Yongsu MA
;
Baoyi LI
;
Xiaodong TIAN
;
Yinmo YANG
Author Information
1. 北京大学第一医院肝胆胰外科,北京 100034
- Keywords:
Pancreatic cancer;
Conversion therapy;
Chemotherapy;
Radiotherapy;
Targeted therapy;
Immunotherapy
- From:
Tumor
2023;43(6):552-558
- CountryChina
- Language:Chinese
-
Abstract:
Pancreatic cancer is the fourth leading cause of cancer-related death in the world.Most patients are diagnosed as locally advanced or metastatic disease at initial visit,losing the opportunity of surgery.Conversion therapy aims to give unresectable tumors the opportunity to receive radical surgery through comprehensive treatment.For unresectable pancreatic cancer,chemotherapy based on AG(abraxane+gemcitabine)or FOLFIRINOX(5-fluorouracil+leucovorin+irinotecan+oxaliplatin),radiotherapy combined with chemotherapy as well as other regimens have shown conversion potential.Targeted therapy and immunotherapy have also become new frontiers of conversion therapy for pancreatic cancer.Focusing on new drugs and new regimens,this review has summarized the latest research progress of conversion therapy for pancreatic cancer.
